Stay updated on PRS-343 & Atezolizumab in HER2+ Solid Tumors Clinical Trial

Sign up to get notified when there's something new on the PRS-343 & Atezolizumab in HER2+ Solid Tumors Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the PRS-343 & Atezolizumab in HER2+ Solid Tumors Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    Page revision updated from v3.4.2 to v3.4.3.
    Difference
    0.1%
    Check dated 2026-03-12T19:50:02.000Z thumbnail image
  2. Check
    12 days ago
    No Change Detected
  3. Check
    19 days ago
    No Change Detected
  4. Check
    33 days ago
    Change Detected
    Summary
    The page now displays a new revision label: Revision: v3.4.2. This is a minor meta-update and does not alter study details or eligibility information.
    Difference
    0.1%
    Check dated 2026-02-12T02:22:00.000Z thumbnail image
  5. Check
    41 days ago
    Change Detected
    Summary
    Revision: v3.4.1 added and v3.4.0 removed; this appears to be an internal version update with no changes to the page content or study information.
    Difference
    0.1%
    Check dated 2026-02-04T12:32:11.000Z thumbnail image
  6. Check
    48 days ago
    Change Detected
    Summary
    A glossary toggle was added and QC/version metadata was updated (Last Update Submitted that Met QC Criteria and Revision: v3.4.0); FEAR Act data labeling was adjusted.
    Difference
    0.2%
    Check dated 2026-01-28T11:11:20.000Z thumbnail image
  7. Check
    62 days ago
    Change Detected
    Summary
    Revision v3.3.4 was added and Revision v3.3.3 was removed; this is a routine page update. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-01-14T03:42:34.000Z thumbnail image
  8. Check
    84 days ago
    Change Detected
    Summary
    The study's location information was reorganized: a consolidated 'Locations' section was added, and the per-state subsections for California, Louisiana, New York, Ohio, and Texas were removed (revision v3.3.3).
    Difference
    0.7%
    Check dated 2025-12-23T17:32:28.000Z thumbnail image

Stay in the know with updates to PRS-343 & Atezolizumab in HER2+ Solid Tumors Clinical Trial

Enter your email address, and we'll notify you when there's something new on the PRS-343 & Atezolizumab in HER2+ Solid Tumors Clinical Trial page.